REFERENCES
1. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Wolters Kluwer; 2018. Available from: https://www.wolterskluwer.com/en/know/cancer-principles-and-practice-of-oncology [Last accessed on 30 May 2022].
2. Chahoud J, Semaan A, Chen Y, et al. Association between β-Genus human papillomavirus and cutaneous squamous cell carcinoma in immunocompetent individuals-a meta-analysis. JAMA Dermatol 2016;152:1354-64.
3. Ettinger SJ, Feldman EC, Cote E. Textbook of veterinary internal medicine - eBook. Elsevier Health Sciences; 2017. Available from: https://play.google.com/store/books/details?id=57XBDQAAQBAJ [Last accessed on 30 May 2022].
4. Vail D. Tumors of the skin and subcutaneous tissues. Withrow & MacEwen’s small animal clinical oncology. Elsevier :2007. pp. 375-401.
5. Hauck ML, Oblak ML. Tumors of the skin and subcutaneous tissues. Withrow and MacEwen’s small animal clinical oncology. Elsevier; 2020. pp. 352-66.
6. O’Neill SH, Newkirk KM, Anis EA, Brahmbhatt R, Frank LA, Kania SA. Detection of human papillomavirus DNA in feline premalignant and invasive squamous cell carcinoma. Vet Dermatol 2011;22:68-74.
7. Luo Q, Wu X, Chang W, et al. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death Differ 2020;27:1981-97.
8. Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, Zhang CP. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010;46:317-22.
9. Brown JA, Yonekubo Y, Hanson N, et al. TGF-β-Induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma. Cell Stem Cell 2017;21:650-664.e8.
10. Garcia-Mayea Y, Mir C, Carballo L, et al. TSPAN1: a novel protein involved in head and neck squamous cell carcinoma chemoresistance. Cancers (Basel) 2020;12:3269.
11. Perri F, Pacelli R, Della Vittoria Scarpati G, et al. Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck 2015;37:763-70.
12. Akervall J, Nandalur S, Zhang J, et al. A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer 2014;50:570-81.
13. Supsavhad W, Dirksen WP, Martin CK, Rosol TJ. Animal models of head and neck squamous cell carcinoma. Vet J 2016;210:7-16.
14. Wypij JM. A naturally occurring feline model of head and neck squamous cell carcinoma. Patholog Res Int 2013;2013:502197.
15. Vail DM, Thamm D, Liptak J. Withrow and MacEwen’s small animal clinical oncology - E-Book. Elsevier Health Sciences; 2019. Available from: https://play.google.com/store/books/details?id=JX2kDwAAQBAJ [Last accessed on 30 May 2022].
16. Lana SE, Ogilvie GK, Withrow SJ, Straw RC, Rogers KS. Feline cutaneous squamous cell carcinoma of the nasal planum and the pinnae: 61 cases. J Am Anim Hosp Assoc 1997;33:329-32.
17. Théon AP, Madewell BR, Shearn VI, Moulton JE. Prognostic factors associated with radiotherapy of squamous cell carcinoma of the nasal plane in cats. J Am Vet Med Assoc 1995;206:991-6.
18. Babington S, Veness MJ, Cakir B, Gebski VJ, Morgan GJ. Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision? ANZ J Surg 2003;73:621-5.
19. Thomson M. Squamous cell carcinoma of the nasal planum in cats and dogs. Clin Tech Small Anim Pract 2007;22:42-5.
20. Stell AJ, Dobson JM, Langmack K. Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid. J Small Anim Pract 2001;42:164-9.
21. Théon AP, VanVechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 1996;57:205-10.
23. Ohnuma T, Selawry OS, Holland JF, et al. Clinical study with bleomycin: tolerance to twice weekly dosage. Cancer 1972;30:914-22.
24. Blum RH, Carter SK, Agre K. A clinical review of bleomycin - a new antineoplastic agent. Cancer 1973;31:903-14.
25. Madathil MM, Bhattacharya C, Yu Z, Paul R, Rishel MJ, Hecht SM. Modified bleomycin disaccharides exhibiting improved tumor cell targeting. Biochemistry 2014;53:6800-10.
26. Mir L, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. General Pharmacology: The Vascular System 1996;27:745-8.
29. Vet—ql01dc01 A. Bleomycin Sulfate (USAN, pINNM). Drugs 1983;17:532-8.
30. Mir LM, Orlowski S, Belehradek J, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991;27:68-72.
31. Maglietti F, Tellado M, De Robertis M, et al. Electroporation as the immunotherapy strategy for cancer in veterinary medicine: state of the art in latin America. Vaccines (Basel) 2020;8:537.
32. Tellado MN, Maglietti FH, Michinski SD, Marshall GR, Signori E. Predictive factors of response to electrochemotherapy in canine oral malignant melanoma. bioRxiv 2019; doi: 10.1101/727164.
33. Lowe R, Gavazza A, Impellizeri JA, Soden DM, Lubas G. The treatment of canine mast cell tumours with electrochemotherapy with or without surgical excision. Vet Comp Oncol 2017;15:775-84.
34. Cemazar M, Tamzali Y, Sersa G, et al. Electrochemotherapy in veterinary oncology. J Vet Intern Med 2008;22:826-31.
35. Kotnik T, Kramar P, Pucihar G, Miklavcic D, Tarek M. Cell membrane electroporation- Part 1: the phenomenon. IEEE Electr Insul Mag 2012;28:14-23.
36. Mir LM. Bases and rationale of the electrochemotherapy. In: Jarm T, Kramar P, Zupanic A, editors. 11th Mediterranean Conference on Medical and Biomedical Engineering and Computing 2007. Berlin: Springer Berlin Heidelberg; 2007. pp. 622-622.
37. Spugnini EP, Baldi A. Electrochemotherapy in veterinary oncology: state-of-the-art and perspectives. Vet Clin North Am Small Anim Pract 2019;49:967-79.
38. Tozon N, Milevoj N, Impellizeri J. Electrochemotherapy in Veterinary Oncology. In: Impellizeri JA, editor. Electroporation in Veterinary Oncology Practice. Cham: Springer International Publishing; 2021. pp. 63-112.
39. Impellizeri JA. Electroporation in veterinary oncology practice: electrochemotherapy and gene electrotransfer for immunotherapy. Springer Nature. Available from: https://books.google.com/books/about/Electroporation_in_Veterinary_Oncology_P.html?hl=&id=JhVQEAAAQBAJ [Last accessed on 30 May 2022].
40. Tellado M, Maglietti F, Impellizeri J. Electrochemotherapy as a multi-modality component of cancer treatment: combinations with surgery, cryosurgery, radiation therapy, and chemotherapy. Electroporation in veterinary oncology practice. Springer, Cham; 2021. pp. 205–16. Available from: https://link.springer.com/chapter/10.1007/978-3-030-80668-2_8 [Last accessed on 30 May 2022].
41. Simčič P, Pierini A, Lubas G, et al. A retrospective multicentric study of electrochemotherapy in the treatment of feline nasal planum squamous cell carcinoma. Vet Sci 2021;8:53.
42. Tellado MN, Maglietti FH, Michinski SD, Marshall GR, Signori E. Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome. Radiol Oncol 2020;54:68-78.
43. Anjos DS, Sierra OR, Spugnini EP, De Nardi AB, Fonseca-Alves CE. Comparison of two different doses of bleomycin in electrochemotherapy protocols for feline cutaneous squamous cell carcinoma nonsegregated from ultraviolet light exposure. Sci Rep 2020;10:18362.
44. Spugnini EP, Baldi A, Vincenzi B, et al. Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol 2007;59:375-81.
45. Miklavčič D, Šemrov D, Mekid H, Mir LM. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochimica et Biophysica Acta (BBA) - General Subjects 2000;1523:73-83.
46. Gehl J, Sersa G, Matthiessen LW, et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 2018;57:874-82.
47. Ivorra A, Mir LM, Rubinsky B. Electric field redistribution due to conductivity changes during tissue electroporation: experiments with a simple vegetal model. In: Dössel O, Schlegel WC, editors. World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany. Berlin: Springer Berlin Heidelberg; 2010. pp. 59-62.
48. Owen LN. TNM classification of tumours in domestic animals; 1980. Available from: https://books.google.com/books/about/TNM_Classification_of_Tumours_in_Domesti.html?hl=&id=wGFDGQAACAAJ [Last accessed on 30 May 2022].
49. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
50. LeBlanc AK, Atherton M, Bentley RT, et al. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol 2021;19:311-52.
51. Čorović S, Mir LM, Miklavčič D. In vivo muscle electroporation threshold determination: realistic numerical models and in vivo experiments. J Membr Biol 2012;245:509-20.
52. Marino M, Luján E, Mocskos E, Marshall G. OpenEP: an open-source simulator for electroporation-based tumor treatments. Sci Rep 2021;11:1423.
53. Maglietti F, Michinski S, Olaiz N, Castro M, Suárez C, Marshall G. The role of pH fronts in tissue electroporation based treatments. PLoS One 2013;8:e80167.
54. Olaiz N, Signori E, Maglietti F, et al. Tissue damage modeling in gene electrotransfer: the role of pH. Bioelectrochemistry 2014;100:105-11.
55. Garden OA, Volk SW, Mason NJ, Perry JA. Companion animals in comparative oncology: one medicine in action. Vet J 2018;240:6-13.
56. National academies of sciences, engineering, and medicine, institute of medicine, board on health care services, national cancer policy forum. The role of clinical studies for pets with naturally occurring tumors in translational cancer research: workshop summary. National Academies Press. 2016. Available from: https://www.nap.edu/21830 [Last accessed on 21 Jun 2022].
57. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203-14.
58. Reif JS. Animal sentinels for environmental and public health. Public Health Rep 2011;126 Suppl 1:50-7.
59. Riccardo F, Aurisicchio L, Impellizeri JA, Cavallo F. The importance of comparative oncology in translational medicine. Cancer Immunol Immunother 2015;64:137-48.
60. Alexander J, Cukierman E. Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. Curr Opin Cell Biol 2016;42:80-93.
61. Coy J, Caldwell A, Chow L, Guth A, Dow S. PD-1 expression by canine T cells and functional effects of PD-1 blockade. Vet Comp Oncol 2017;15:1487-502.
62. Gehl J, Sersa G. Electrochemotherapy and its clinical applications. In: Miklavcic D, editor. Handbook of Electroporation. Cham: springer International Publishing; 2017. pp. 1-16.
63. Torrigiani F, Pierini A, Lowe R, Simčič P, Lubas G. Soft tissue sarcoma in dogs: a treatment review and a novel approach using electrochemotherapy in a case series. Vet Comp Oncol 2019;17:234-41.
64. Kodre V, Cemazar M, Pecar J, Sersa G, Cőr A, Tozon N. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo 2009;23:55-62.
65. Spugnini EP, Scacco L, Bolaffio C, Baldi A. Electrochemotherapy for the treatment of cutaneous solid tumors in equids: a retrospective study. Open Vet J 2021;11:385-9.
66. Tozon N, Kramaric P, Kos Kadunc V, Sersa G, Cemazar M. Electrochemotherapy as a single or adjuvant treatment to surgery of cutaneous sarcoid tumours in horses: a 31-case retrospective study. Vet Rec 2016;179:627.
67. Brunner CH, Dutra G, Silva CB, Silveira LM, Martins Mde F. Electrochemotherapy for the treatment of fibropapillomas in Chelonia mydas. J Zoo Wildl Med 2014;45:213-8.
68. Tunev SS, Wells MG. Cutaneous melanoma in a ferret (Mustela putorius furo). Vet Pathol 2002;39:141-3.
70. Qin Z, Jiang J, Long G, Bischof JC. . Irreversible electroporation: an in vivo study within the dorsal skin fold chamber. American Society of Mechanical Engineers Digital Collection.
71. Aycock KN, Davalos RV. Irreversible electroporation: background, theory, and review of recent developments in clinical oncology. Bioelectricity 2019;1:214-34.
72. Tozon N, Pavlin D, Sersa G, Dolinsek T, Cemazar M. Electrochemotherapy with intravenous bleomycin injection: an observational study in superficial squamous cell carcinoma in cats. J Feline Med Surg 2014;16:291-9.
73. David E, Blanchard F, Heymann MF, et al. The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma 2011;2011:932451.
74. Corovic S, Lackovic I, Sustaric P, Sustar T, Rodic T, Miklavcic D. Modeling of electric field distribution in tissues during electroporation. Biomed Eng Online 2013;12:16.
75. Maglietti F, Tellado M, Olaiz N, Michinski S, Marshall G. Combined local and systemic bleomycin administration in electrochemotherapy to reduce the number of treatment sessions. Radiol Oncol 2016;50:58-63.
76. Spugnini EP, Vincenzi B, Carocci F, Bonichi C, Menicagli F, Baldi A. Combination of bleomycin and cisplatin as adjuvant electrochemotherapy protocol for the treatment of incompletely excised feline injection-site sarcomas: a retrospective study. Open Vet J 2020;10:267-71.
77. Murphy S. Cutaneous squamous cell carcinoma in the cat: current understanding and treatment approaches. J Feline Med Surg 2013;15:401-7.
78. Bexfield NH, Stell AJ, Gear RN, Dobson JM. Photodynamic therapy of superficial nasal planum squamous cell carcinomas in cats: 55 cases. J Vet Intern Med 2008;22:1385-9.
79. Queiroz GF, Matera JM, Zaidan Dagli ML. Clinical study of cryosurgery efficacy in the treatment of skin and subcutaneous tumors in dogs and cats. Vet Surg 2008;37:438-43.
80. Cindrič H, Kos B, Miklavčič D. Electrodes and electric field distribution in clinical practice. In: Impellizeri JA, editor. Electroporation in Veterinary Oncology Practice. Cham: Springer International Publishing; 2021. pp. 21-59.
